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enced a greater degree of pain and discomfort as mea-
sured by the EQ-5D (P = 0.018) and a lower perception
of their health status using the EQ-VAS (P = 0.039). 
Statistically signiﬁcant differences between both groups
were detected in all domains of the VFQ-25, except
general and colour vision, although differences were
thought to be clinically signiﬁcant only for the ocular pain
domain. The RQLQ scores were also all found to differ
signiﬁcantly between groups (P < 0.001). The total of
both the public health care and private out-of-pockets
costs of SAC in our study population ranged on average
between £64.61 for a pensioner to £142.29 for a person
with SAC in paid employment. CONCLUSIONS: SAC is
a costly, highly prevalent, chronic condition associated
with signiﬁcant reductions in both ocular and general
quality of life, as well as ongoing out-of-pocket expenses
and health care costs.
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OBJECTIVES: To estimate the number of quality
adjusted life years (QALYs) for chronic, treatment-
resistant heroin addicts in the Netherlands during the 
ﬁrst year of treatment with either oral methadone alone
or oral methadone in combination with co-prescribed
heroin. METHODS: Randomly assigned patients (N =
430) completed EuroQol-5D questionnaires at months 2,
6, 10, and 12 after they started therapy. Utility values
were derived by applying existing time trade-off based
regression weights to the data. It was assumed that the
observed EuroQol scores and related utilities reﬂected 
the health status between the actual measurement and the
previous one available. In case of missing endpoint assess-
ments, the last observation was carried forward. QALYs
were calculated as the mean health utility during follow-
up, weighted for the number of months preceding each
follow-up measurement. It was hypothesized that co-
prescription of heroin would lead to more QALYs.
RESULTS: About half of all treatment-resistant heroin
addicts suffered pain or discomfort and felt anxious or
depressed at baseline. In the ﬁrst year of treatment, a
patient on oral methadone alone generated 0.830 QALYs
on average (upper bound one-sided 95% conﬁdence
interval: 0.846), a patient on co-prescribed heroin 0.867
QALYs (lower bound one-sided 95% conﬁdence interval:
0.852). The numbers of QALYs generated per patient dif-
fered for the two groups (t = -2.72, p = 0.003 one-tailed).
Hence, the medical co-prescription of heroin resulted, on
average, in a 21.4% reduction of existing health loss.
CONCLUSIONS: Medical co-prescription of heroin in
addition to an oral methadone regimen is superior to an
oral methadone alone regimen. Further study will focus
on the cost-utility of co-prescribed heroin in this patient
population with special attention to the balance of
increasing health care costs and decreasing costs of illegal
behavior by the heroin addicts in the program.
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OBJECTIVES: Bulimia nervosa (BN) is characterised by
recurrent episodes of binge eating and secondly by com-
pensatory behaviour to prevent weight gain. Its preva-
lence has been estimated between 0.5% and 1.0% in
young women. A recent clinical guideline was commis-
sioned to establish the optimum clinical management of
BN in the UK. Antidepressants and bulimia nervosa spe-
ciﬁc cognitive behaviour therapy (CBT-BN) were identi-
ﬁed as the leading pharmacological and psychological
therapies in the clinical review. This study reports the
results of the cost-effectiveness analysis of these strategies
conducted as part of the guideline development process.
METHODS: A decision analytic model was developed to
calculate the incremental cost-effectiveness of antidepres-
sant therapy (ﬂuoxetine), CBT-BN and their combination
from the NHS’s viewpoint. Remission data were obtained
from the guideline meta-analyses, resource use data were
collected from the literature and experts. Unit costs were
calculated for year 2002/03. Different baseline scenarios
and uncertainty around the estimates (probabilistic analy-
sis) were explored. RESULTS: Combination therapy is
dominated by the other two strategies and was excluded
from the ﬁnal calculation. CBT-BN is more effective and
has higher treatment costs than ﬂuoxetine prescribed in
primary care with an incremental cost-effectiveness ratio
(ICER) of £4,807. The probability of CBT-BN being cost-
effective is 50% if decision makers are willing to pay
between £4,000–£5,000 for an additional successfully
treated BN case, but it increases to approximately 95%
if the threshold value is £10,000. CONCLUSIONS: Sig-
niﬁcant uncertainty around these results still exists (e.g.
the true cost of side effects of antidepressant therapy are
unknown, nor have attempts been made to quantify pos-
sible costs averted due to successful treatment). When
further research is carried out, it will be necessary to re-
estimate the cost-effectiveness of each alternative incor-
porating such inﬂuences. However, all these inﬂuences are
